This minireview discusses how information on the mechanisms by which ADRB2 activation inhibits apoptosis can be used to guide clinical trials of ADRB2 antagonist propranolol as potential life-extending therapy for prostate cancer. The gene discussed is ADRB2; the disease is Familial prostate cancer.